Triad Therapeutics Inc.
This article was originally published in Start Up
Triad Therapeutics Inc. hopes to accelerate the drug discovery process through the use of its IOPE technology, which it claims significantly accelerates the discovery of nanomolar-affinity hits over those obtained with other currently available technologies. IOPE exploits NMR spectroscopy to map key structural elements among the members of individual classes of enzymes and then uses the data to design libraries of compounds biased to bind to targets of the class, in effect starting the medicinal chemistry process with a compound that is much closer to a development lead.
You may also be interested in...
Kinetix Pharmaceuticals hoped that a focus on a particular class of targets that shares structural similarities--the protein kinases--would yield small molecules for a variety of therapeutic areas. But in order to realize synergies between multiple research projects in protein kinases, the company couldn't partner the projects out to numerous pharmaceutical partners, each requiring exclusivity and confidentiality. After technological rival Vertex signed a multi-million dollar protein kinase development partnership with Novartis, Kinetix began to rethink its original business model. A $170 million acquisition offer by Amgen Inc. made strategic sense for the start-up.
The first generation less-invasive devices for abdominal aortic aneurysm (AAA) surgery haven't yet been approved and the next generation is already here.
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?